{"id":"https://openalex.org/W7222922112","doi":"https://doi.org/10.1158/2767-9764.crc-26-0571","title":"Paxalisib with Trastuzumab for HER2-Positive Metastatic Breast Cancer with Active Brain Metastases: A Phase II Trial with Integrated Plasma and CSF ctDNA Analyses","display_name":"Paxalisib with Trastuzumab for HER2-Positive Metastatic Breast Cancer with Active Brain Metastases: A Phase II Trial with Integrated Plasma and CSF ctDNA Analyses","publication_year":2026,"publication_date":"2026-10-19","ids":{"openalex":"https://openalex.org/W7222922112","doi":"https://doi.org/10.1158/2767-9764.crc-26-0571","pmid":"https://pubmed.ncbi.nlm.nih.gov/42895898"},"language":"en","primary_location":{"id":"doi:10.1158/2767-9764.crc-26-0571","doi":"https://doi.org/10.1158/2767-9764.crc-26-0571","is_oa":true,"landing_page_url":"https://doi.org/10.1158/2767-9764.crc-26-0571","pdf_url":null,"source":{"id":"https://openalex.org/S4210217028","display_name":"Cancer Research Communications","issn_l":"2767-9764","issn":["2767-9764"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","jufo-1","ki-jl-1","medline","norway-1"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research Communications","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1158/2767-9764.crc-26-0571","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5090500701","display_name":"Elia Segu\u00ed","orcid":"https://orcid.org/0000-0001-7770-9825","observed_orcids":["https://orcid.org/0000-0001-7770-9825"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Elia Segui","raw_affiliation_strings":["Dana-Farber Cancer Institute 2 Boston, MA"],"raw_orcid":"https://orcid.org/0000-0001-7770-9825","affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute 2 Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042886213","display_name":"Jorge G\u00f3mez Tejeda Za\u00f1udo","orcid":"https://orcid.org/0000-0002-1092-0068","observed_orcids":["https://orcid.org/0000-0002-1092-0068"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jorge Gomez Tejeda Za\u00f1udo","raw_affiliation_strings":["Dana-Farber Cancer Institute 1 Boston"],"raw_orcid":"https://orcid.org/0000-0002-1092-0068","affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute 1 Boston","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090301769","display_name":"Noah Graham","orcid":"https://orcid.org/0009-0009-0622-683X","observed_orcids":["https://orcid.org/0009-0009-0622-683X"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Noah Graham","raw_affiliation_strings":["Dana-Farber Cancer Institute 3 Boston, Massachusetts"],"raw_orcid":"https://orcid.org/0009-0009-0622-683X","affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute 3 Boston, Massachusetts","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5159039385","display_name":"Patrick T. Kurnia","orcid":"https://orcid.org/0009-0009-8263-3314","observed_orcids":["https://orcid.org/0009-0009-8263-3314"]},"institutions":[{"id":"https://openalex.org/I107606265","display_name":"Broad Institute","ror":"https://ror.org/05a0ya142","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I107606265"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Patrick T. Kurnia","raw_affiliation_strings":["Broad Institute 4"],"raw_orcid":"https://orcid.org/0009-0009-8263-3314","affiliations":[{"raw_affiliation_string":"Broad Institute 4","institution_ids":["https://openalex.org/I107606265"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021979487","display_name":"Andrea N. Perry","orcid":"https://orcid.org/0000-0001-6769-5490","observed_orcids":["https://orcid.org/0000-0001-6769-5490"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andrea N. Perry","raw_affiliation_strings":["Dana-Farber Cancer Institute 2 Boston, MA"],"raw_orcid":"https://orcid.org/0000-0001-6769-5490","affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute 2 Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062515397","display_name":"Nabihah Tayob","orcid":"https://orcid.org/0000-0001-6088-167X","observed_orcids":["https://orcid.org/0000-0001-6088-167X"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nabihah Tayob","raw_affiliation_strings":["Dana-Farber Cancer Institute 3 Boston, Massachusetts"],"raw_orcid":"https://orcid.org/0000-0001-6088-167X","affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute 3 Boston, Massachusetts","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088801158","display_name":"Heather Anne Parsons","orcid":"https://orcid.org/0000-0001-8178-6612","observed_orcids":["https://orcid.org/0000-0001-8178-6612"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Heather A. Parsons","raw_affiliation_strings":["Dana-Farber Cancer Institute 2 Boston, MA"],"raw_orcid":"https://orcid.org/0000-0001-8178-6612","affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute 2 Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000879533","display_name":"Raechel Davis","orcid":"https://orcid.org/0009-0009-0213-8680","observed_orcids":["https://orcid.org/0009-0009-0213-8680"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Raechel Davis","raw_affiliation_strings":["Dana-Farber Cancer Institute 2 Boston, MA"],"raw_orcid":"https://orcid.org/0009-0009-0213-8680","affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute 2 Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031580629","display_name":"Molly K. DiLullo","orcid":"https://orcid.org/0009-0005-1036-796X","observed_orcids":["https://orcid.org/0009-0005-1036-796X"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Molly K. DiLullo","raw_affiliation_strings":["Dana-Farber Cancer Institute 1 Boston"],"raw_orcid":"https://orcid.org/0009-0005-1036-796X","affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute 1 Boston","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034294856","display_name":"Jennifer A. Ligibel","orcid":"https://orcid.org/0000-0002-0633-3151","observed_orcids":["https://orcid.org/0000-0002-0633-3151"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jennifer A. Ligibel","raw_affiliation_strings":["Dana-Farber Cancer Institute 2 Boston, MA"],"raw_orcid":"https://orcid.org/0000-0002-0633-3151","affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute 2 Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003348942","display_name":"Filipa C. Lynce","orcid":"https://orcid.org/0000-0001-6615-7076","observed_orcids":["https://orcid.org/0000-0001-6615-7076"]},"institutions":[{"id":"https://openalex.org/I4210134579","display_name":"Dana-Farber/Harvard Cancer Center","ror":"https://ror.org/03pvyf116","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I136199984","https://openalex.org/I4210117453","https://openalex.org/I4210134579"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Filipa Lynce","raw_affiliation_strings":["Dana-Farber/Harvard Cancer Center 5 Boston, MA"],"raw_orcid":"https://orcid.org/0000-0001-6615-7076","affiliations":[{"raw_affiliation_string":"Dana-Farber/Harvard Cancer Center 5 Boston, MA","institution_ids":["https://openalex.org/I4210134579"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000656932","display_name":"Jing Ni","orcid":"https://orcid.org/0000-0002-4229-775X","observed_orcids":["https://orcid.org/0000-0002-4229-775X"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jing Ni","raw_affiliation_strings":["Dana-Farber Cancer Institute 2 Boston, MA"],"raw_orcid":"https://orcid.org/0000-0002-4229-775X","affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute 2 Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069056507","display_name":"Sara M. Tolaney","orcid":"https://orcid.org/0000-0002-5940-8671","observed_orcids":["https://orcid.org/0000-0002-5940-8671"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sara M. Tolaney","raw_affiliation_strings":["Dana-Farber Cancer Institute 3 Boston, Massachusetts"],"raw_orcid":"https://orcid.org/0000-0002-5940-8671","affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute 3 Boston, Massachusetts","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070245248","display_name":"Eric P. Winer","orcid":"https://orcid.org/0000-0002-8819-1723","observed_orcids":["https://orcid.org/0000-0002-8819-1723"]},"institutions":[{"id":"https://openalex.org/I32971472","display_name":"Yale University","ror":"https://ror.org/03v76x132","country_code":"US","type":"education","lineage":["https://openalex.org/I32971472"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Eric P. Winer","raw_affiliation_strings":["Yale University 6"],"raw_orcid":"https://orcid.org/0000-0002-8819-1723","affiliations":[{"raw_affiliation_string":"Yale University 6","institution_ids":["https://openalex.org/I32971472"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089866079","display_name":"Adrienne Gropper Waks","orcid":"https://orcid.org/0000-0001-5649-7229","observed_orcids":["https://orcid.org/0000-0001-5649-7229"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Adrienne G. Waks","raw_affiliation_strings":["Dana-Farber Cancer Institute 2 Boston, MA"],"raw_orcid":"https://orcid.org/0000-0001-5649-7229","affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute 2 Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043714628","display_name":"Jean J. Zhao","orcid":"https://orcid.org/0000-0002-4561-5688","observed_orcids":["https://orcid.org/0000-0002-4561-5688"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jean Zhao","raw_affiliation_strings":["Dana-Farber Cancer Institute 2 Boston, MA"],"raw_orcid":"https://orcid.org/0000-0002-4561-5688","affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute 2 Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051714606","display_name":"Rinath M. Jeselsohn","orcid":"https://orcid.org/0000-0001-7996-7529","observed_orcids":["https://orcid.org/0000-0001-7996-7529"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rinath M. Jeselsohn","raw_affiliation_strings":["Dana-Farber Cancer Institute 2 Boston, MA"],"raw_orcid":"https://orcid.org/0000-0001-7996-7529","affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute 2 Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022319770","display_name":"NU Lin","orcid":"https://orcid.org/0000-0003-2263-5413","observed_orcids":["https://orcid.org/0000-0003-2263-5413"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nancy U. Lin","raw_affiliation_strings":["Dana-Farber Cancer Institute 2 Boston, MA"],"raw_orcid":"https://orcid.org/0000-0003-2263-5413","affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute 2 Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5055137470","display_name":"Jos\u00e9 Pablo Leone","orcid":"https://orcid.org/0000-0002-8537-652X","observed_orcids":["https://orcid.org/0000-0002-8537-652X"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Jos\u00e9 P. Leone","raw_affiliation_strings":["Dana-Farber Cancer Institute 1 Boston"],"raw_orcid":"https://orcid.org/0000-0002-8537-652X","affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute 1 Boston","institution_ids":["https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5055137470"],"corresponding_institution_ids":["https://openalex.org/I4210117453"],"apc_list":{"value":2550,"currency":"USD","value_usd":2550},"apc_paid":{"value":2550,"currency":"USD","value_usd":2550},"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.77387559,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11600","display_name":"Brain Metastases and Treatment","score":0.9121000170707703,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11600","display_name":"Brain Metastases and Treatment","score":0.9121000170707703,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.03189999982714653,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10129","display_name":"Glioma Diagnosis and Treatment","score":0.009399999864399433,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/paxalisib","display_name":"paxalisib","score":0.9520000219345093},{"id":"https://openalex.org/keywords/trastuzumab","display_name":"trastuzumab","score":0.9980000257492065},{"id":"https://openalex.org/keywords/her2-positive-breast-cancer","display_name":"HER2-positive breast cancer","score":0.9980000257492065},{"id":"https://openalex.org/keywords/brain-metastases","display_name":"brain metastases","score":0.9890000224113464},{"id":"https://openalex.org/keywords/pi3k-mtor-inhibition","display_name":"PI3K/mTOR inhibition","score":0.9049999713897705},{"id":"https://openalex.org/keywords/dual-pi3k-mtor-inhibitor","display_name":"PI3K/mTOR dual inhibitor","score":0.8560000061988831},{"id":"https://openalex.org/keywords/plasma-ctdna","display_name":"plasma ctDNA","score":0.9710000157356262},{"id":"https://openalex.org/keywords/leptomeningeal-metastasis","display_name":"leptomeningeal metastasis","score":0.699999988079071},{"id":"https://openalex.org/keywords/treatment-response-biomarkers","display_name":"treatment response biomarkers","score":0.5199999809265137}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8716999888420105},{"id":"https://openalex.org/C2779786085","wikidata":"https://www.wikidata.org/wiki/Q412616","display_name":"Trastuzumab","level":4,"score":0.8252000212669373},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6169000267982483},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.6014000177383423},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5989999771118164},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.5713000297546387},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.4754999876022339},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.43479999899864197},{"id":"https://openalex.org/C2779651940","wikidata":"https://www.wikidata.org/wiki/Q54196","display_name":"Cerebrospinal fluid","level":2,"score":0.4284000098705292},{"id":"https://openalex.org/C2780283643","wikidata":"https://www.wikidata.org/wiki/Q2110267","display_name":"Primary tumor","level":4,"score":0.40560001134872437},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.3921000063419342},{"id":"https://openalex.org/C2779130545","wikidata":"https://www.wikidata.org/wiki/Q233309","display_name":"Brain tumor","level":2,"score":0.32600000500679016},{"id":"https://openalex.org/C3018260909","wikidata":"https://www.wikidata.org/wiki/Q1322871","display_name":"Exploratory analysis","level":2,"score":0.325300008058548},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.3197999894618988},{"id":"https://openalex.org/C2778164965","wikidata":"https://www.wikidata.org/wiki/Q1620196","display_name":"Brain metastasis","level":4,"score":0.2915000021457672},{"id":"https://openalex.org/C529278444","wikidata":"https://www.wikidata.org/wiki/Q47273","display_name":"Central nervous system","level":2,"score":0.2757999897003174},{"id":"https://openalex.org/C61238886","wikidata":"https://www.wikidata.org/wiki/Q5121689","display_name":"Circulating tumor cell","level":4,"score":0.2676999866962433},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.26499998569488525},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.26409998536109924}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1158/2767-9764.crc-26-0571","doi":"https://doi.org/10.1158/2767-9764.crc-26-0571","is_oa":true,"landing_page_url":"https://doi.org/10.1158/2767-9764.crc-26-0571","pdf_url":null,"source":{"id":"https://openalex.org/S4210217028","display_name":"Cancer Research Communications","issn_l":"2767-9764","issn":["2767-9764"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","jufo-1","ki-jl-1","medline","norway-1"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research Communications","raw_type":"journal-article"},{"id":"pmid:42895898","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/42895898","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer research communications","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1158/2767-9764.crc-26-0571","doi":"https://doi.org/10.1158/2767-9764.crc-26-0571","is_oa":true,"landing_page_url":"https://doi.org/10.1158/2767-9764.crc-26-0571","pdf_url":null,"source":{"id":"https://openalex.org/S4210217028","display_name":"Cancer Research Communications","issn_l":"2767-9764","issn":["2767-9764"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","jufo-1","ki-jl-1","medline","norway-1"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research Communications","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4411287599","https://openalex.org/W3201649178","https://openalex.org/W4413105908","https://openalex.org/W4311512788","https://openalex.org/W2810914812","https://openalex.org/W4388590602","https://openalex.org/W4379283781","https://openalex.org/W2410979882","https://openalex.org/W2621422678","https://openalex.org/W2062773606"],"abstract_inverted_index":{"PURPOSE:":[0],"HER2+":[1,12,46,227,247],"breast":[2],"cancer":[3],"brain":[4],"metastases":[5],"(BCBM)":[6],"frequently":[7],"harbor":[8],"PI3K/AKT/mTOR":[9],"alterations.":[10],"Preclinical":[11],"BCBM":[13,47],"models":[14],"demonstrated":[15],"durable":[16],"tumor":[17,107,190,201,205,238],"regression":[18],"with":[19,37,177,182,196,210],"dual":[20,33],"PI3K":[21],"and":[22,48,102,116,162,240],"mTOR":[23],"inhibition.":[24,184],"Our":[25],"phase":[26,68],"II":[27,69],"trial":[28,59],"evaluated":[29],"paxalisib,":[30],"a":[31,61,178],"brain-penetrant":[32],"PI3K/mTOR":[34,183],"inhibitor,":[35],"combined":[36,209],"trastuzumab.":[38],"PATIENTS":[39],"AND":[40],"METHODS:":[41],"Eligible":[42],"patients":[43,121,146],"had":[44],"active/progressive":[45],"could":[49],"have":[50],"received":[51],"prior":[52,130],"therapies;":[53],"leptomeningeal":[54],"disease":[55],"was":[56,79,110,139,171,175,212],"excluded.":[57],"The":[58,76],"included":[60],"safety":[62,179],"run-in":[63],"to":[64],"determine":[65],"the":[66,98,142,149,163,218],"recommended":[67],"dose":[70],"(RP2D),":[71],"followed":[72],"by":[73],"expansion":[74],"cohorts.":[75],"primary":[77,219],"endpoint":[78,220],"confirmed":[80,152],"central":[81],"nervous":[82],"system":[83],"(CNS)":[84],"objective":[85],"response":[86,242],"rate":[87],"(ORR)":[88],"per":[89],"Response":[90],"Assessment":[91],"in":[92,192,199,224,246],"Neuro-Oncology":[93],"Brain":[94],"Metastases":[95],"criteria":[96],"at":[97,148],"RP2D.":[99,143],"Paired":[100],"plasma":[101,244],"cerebrospinal":[103],"fluid":[104],"(CSF)":[105],"circulating":[106],"DNA":[108],"(ctDNA)":[109],"analyzed":[111],"using":[112],"ultra-low-pass":[113],"whole-genome":[114],"sequencing":[115],"whole-exome":[117],"sequencing.":[118],"RESULTS:":[119],"Seventeen":[120],"were":[122],"treated":[123,147],"(median":[124],"age":[125],"44":[126],"years;":[127],"median":[128],"5":[129],"therapy":[131],"lines).":[132],"Paxalisib":[133,208],"30":[134],"mg":[135],"daily":[136],"plus":[137],"trastuzumab":[138,211],"established":[140],"as":[141],"Among":[144],"12":[145],"RP2D,":[150],"no":[151],"CNS":[153,204,222],"responses":[154],"occurred":[155],"(CNS":[156],"ORR,":[157],"0%;":[158],"95%":[159],"CI,":[160],"0.0-26.5%),":[161],"study":[164],"closed":[165],"for":[166],"futility.":[167],"Median":[168],"overall":[169],"survival":[170],"16.5":[172],"months.":[173],"Treatment":[174],"feasible,":[176],"profile":[180],"consistent":[181],"Exploratory":[185,229],"ctDNA":[186,234,245],"analyses":[187],"showed":[188],"higher":[189],"fraction":[191,202],"CSF":[193,200],"than":[194,243],"plasma,":[195],"longitudinal":[197],"changes":[198],"paralleling":[203],"burden.":[206],"CONCLUSIONS:":[207],"feasible":[213],"but":[214],"did":[215],"not":[216],"meet":[217],"of":[221],"ORR":[223],"heavily":[225],"pretreated":[226],"BCBM.":[228,248],"findings":[230],"suggest":[231],"that":[232],"CSF-derived":[233],"may":[235],"better":[236],"capture":[237],"genomics":[239],"treatment":[241],".":[249]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2026-10-20T00:00:00"}